Radiation Toxicity - Pipeline Review, Q1 2011

Description: Radiation Toxicity - Pipeline Review, Q1 2011

Summary

Global Markets Direct's, 'Radiation Toxicity - Pipeline Review, Q1 2011', provides an overview of the Radiation Toxicity therapeutic pipeline. This report provides information on the therapeutic development for Radiation Toxicity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Radiation Toxicity. 'Radiation Toxicity - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Radiation Toxicity.
- A review of the Radiation Toxicity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Radiation Toxicity pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Radiation Toxicity pipeline depth and focus of Radiation Toxicity therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Radiation Toxicity Overview
Therapeutics Development
An Overview of Pipeline Products for Radiation Toxicity
Radiation Toxicity Therapeutics under Development by Companies
Radiation Toxicity Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Radiation Toxicity Therapeutics Development
Genzyme Corporation
F. Hoffmann-La Roche Ltd.
Daichi Sankyo Company, Ltd
Gamida Cell Ltd.
Nanotherapeutics, Inc.
Maxygen, Inc.
Aeolus Pharmaceuticals, Inc.
Hollis-Eden Pharmaceuticals, Inc.
Cleveland BioLabs, Inc.
Cellerant Therapeutics, Inc.
Meabco A/S
Onconova Therapeutics, Inc
Canopus BioPharma Incorporated
Universities/Institutes Involved in Radiation Toxicity Therapeutics Development
Radiation Toxicity Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Cevimeline Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prochymal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
amifostine trihydrate + cisplatin + fluorouracil + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cetuximab + paclitaxel + carboplatin + radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mometasone Furoate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ramosetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Toxicity - Featured News
Nov 30, 2010: Cleveland BioLabs Receives US Orphan Drug Status For CBLB502 For Treatment Of Exposure To Radiation
Nov 02, 2010: Aeolus’ AEOL 10150 Promotes Survival In Non-Human Primates Exposed To Lethal Doses Of Radiation
Sep 29, 2010: Cleveland BioLabs Announces Results Of Second Safety Study For CBLB502
Sep 27, 2010: Onconova Presents New Data Demonstrating Radioprotection By Ex-RAD At Radiation Research Society Annual Meeting
Sep 01, 2010: Cellerant Receives $153 Million Contract From BARDA To Develop Treatment For Acute
Radiation Syndrome
Aug 31, 2010: ImmuneRegen Invited To Submit Full Proposal To BARDA For Homspera As Potential Medical Countermeasure For Injury Associated With Radiation Exposure
Aug 30, 2010: Nanotherapeutics Submits IND Application To FDA For Clinical Testing Of NanoDTPA To Treat Radiation Exposure
Jan 23, 2009: Onconova And DoD Collaborators Publish Research Demonstrating Increased Survivability Of Previously Lethal Radiation In Mice With Ex-RAD

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Radiation Toxicity, 2011
Products under Development for Radiation Toxicity – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Pre-Clinical Stage Development, 2011
Genzyme Corporation, 2011
F. Hoffmann-La Roche Ltd., 2011
Daiichi Sankyo Company, Ltd, 2011
Gamida Cell Ltd., 2011
Nanotherapeutics, Inc., 2011
Maxygen, Inc., 2011
Aeolus Pharmaceuticals, Inc., 2011
Hollis-Eden Pharmaceuticals, Inc., 2011
Cleveland BioLabs, Inc., 2011
Cellerant Therapeutics, Inc., 2011
Meabco A/S, 2011
Onconova Therapeutics, Inc, 2011
Canopus BioPharma Incorporated, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011

List of Figures
Number of Products under Development for Radiation Toxicity, 2011
Products under Development for Radiation Toxicity – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Radiation Toxicity - Pipeline Review, Q1 2011
Web Address: http://www.researchandmarkets.com/reports/1524626/
Office Code: SCD21WYP

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ____________________________________________ Last Name: _______________________________________
Email Address: * ________________________________________
Job Title: ______________________________________________
Organisation: ___________________________________________
Address: _______________________________________________
City: ___________________________________________________
Postal / Zip Code: _______________________________________
Country: _______________________________________________
Phone Number: __________________________________________
Fax Number: ____________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp